Appia Bio Inc. raised $52 million in a series A funding round to bring forward a novel take on allogeneic cell therapy for cancer, based on a rare lymphocyte population, invariant natural killer T (iNKT) cells, which exhibit aspects of both NK cell and T-cell biology.

PERTH, Australia – The FDA granted Oncores Medical Pty. Ltd. breakthrough device designation for its quantitative micro-elastography (QME) imaging system. The hand-held imaging tool helps surgeons differentiate between cancerous and healthy tissue in real time at the point of surgery, and it could substantially improve outcomes in breast-conserving surgery (BCS) and reduce repeat operations for women with breast cancer.